EC
Euclidean Capital Portfolio holdings
AUM
$306M
This Quarter Return
+11.94%
1 Year Return
+16.69%
3 Year Return
+17.66%
5 Year Return
–
10 Year Return
–
AUM
$889M
AUM Growth
+$889M
(+94%)
Cap. Flow
+$370M
Cap. Flow
% of AUM
41.64%
Top 10 Holdings %
Top 10 Hldgs %
99.81%
Holding
13
New
–
Increased
2
Reduced
1
Closed
–
Top Buys
| 1 |
SPDR S&P 500 ETF Trust
SPY
|
$319M |
| 2 |
SPDR Gold Trust
GLD
|
$62.6M |
Top Sells
| 1 |
Surrozen
SRZN
|
$11.5M |
Sector Composition
| 1 | Healthcare | 7.71% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
|
1
SPDR S&P 500 ETF Trust
SPY
$658B
| $436M | 49.06% |
917,141
+670,891
| +272% | +$319M |
|
|
2
SPDR Gold Trust
GLD
$107B
| $266M | 29.91% |
1,390,000
+327,500
| +31% | +$62.6M |
|
3
iShares MSCI India ETF
INDA
$9.17B
| $118M | 13.32% |
2,425,144
| – | – |
|
4
RAPT Therapeutics
RAPT
$188M
| $16.3M | 1.84% |
657,899
| – | – |
|
5
Alector
ALEC
$238M
| $10.4M | 1.17% |
1,307,858
| – | – |
|
6
Foghorn Therapeutics
FHTX
$286M
| $10.2M | 1.14% |
1,573,761
| – | – |
|
|
ME
7
DELISTED
23andMe Holding Co. Class A Common Stock
ME
| $9.36M | 1.05% |
10,243,122
| – | – |
|
8
Oric Pharmaceuticals
ORIC
$994M
| $9.1M | 1.02% |
989,410
| – | – |
|
9
PMV Pharmaceuticals
PMVP
$74.2M
| $8.15M | 0.92% |
2,627,643
| – | – |
|
10
Tenaya Therapeutics
TNYA
$184M
| $3.29M | 0.37% |
1,015,705
| – | – |
|
|
NGM
11
DELISTED
NGM Biopharmaceuticals, Inc. Common Stock
NGM
| $852K | 0.1% |
992,168
| – | – |
|
|
12
Surrozen
SRZN
$104M
| $824K | 0.09% |
87,696
-1,227,767
| -93% | -$11.5M |
|
|
13
Surrozen, Inc. Warrant
SRZNW
$71.6K
| $3.31K | ﹤0.01% |
170,833
| – | – |
|